systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-325Research ArticleОБЗОРЫЛерканидипин – антагонист кальция III поколения: обзор эффективности в терапии артериальной гипертензииLercanidipine as a calcium antagonist of the third generation: a review of effectiveness in the hypertension treatmentЗадионченкоВ. С.ZadionchenkoV. S.noemail@neicon.ruШехянГ. Г.ShekhyanG. G.noemail@neicon.ruЯлымовА. А.YalymovA. A.noemail@neicon.ruВаренцовС. И.VarentsovS. I.noemail@neicon.ruГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РоссииRussian FederationГБУЗ Городская клиническая больница №11 Департамента здравоохранения г. МосквыRussian Federation2013231220221047679Copyright © Задионченко В.С., Шехян Г.Г., Ялымов А.А., Варенцов С.И., 20222022Задионченко В.С., Шехян Г.Г., Ялымов А.А., Варенцов С.И.Zadionchenko V.S., Shekhyan G.G., Yalymov A.A., Varentsov S.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/325

В статье представлены данные клинических исследований, в которых изучались эффективность и безопасность современного антагониста кальция (АК) III поколения лерканидипина. Результаты исследований демонстрируют, что лечение лерканидипином приводит к выраженному снижению систолического и диастолического артериального давления без существенного влияния на частоту сердечных сокращений. Уникальные фармакокинетические особенности препарата обеспечивают его эффективность и высокий профиль безопасности, хорошую переносимость, удобство приема и высокую приверженность лечению данным АК у пациентов с артериальной гипертензией. Дополнительные свойства лерканидипина позволяют рекомендовать применение данного АК при сочетанной патологии.

The data from clinical trials that have examined the efficacy and safety of modern third generation calcium antagonist-lercanidipine is presented herein. Results of the following studies demonstrate that treatment with lercanidipine leads to a marked reduction in systolic and diastolic blood pressure without a significant impact on heart rate. Unique pharmacokinetic characteristics of the drug provide its high efficacy and safety, tolerability, convenience, acceptance and high adherence of the said CA in AH patients. Additional lercanidipine properties allow us to recommend the use of this CA in associated pathology cases.

лерканидипинлеркамендигидропиридиныантагонисты кальция III поколениярандомизированные клинические исследованияартериальная гипертензияlercanidipinelercamendihydropyridines calcium antagonists of the third generationrandomized clinical trialshypertensionReferencesBang L, Chapman T, Goa K. Lercanidipine – a review of its efficacy in management of hypertension. Drugs 2003; 22: 2449–72.Bang L, Chapman T, Goa K. Lercanidipine – a review of its efficacy in management of hypertension. Drugs 2003; 22: 2449–72.Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 3: 203–12.Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 3: 203–12.Zanchetti A. Emerging data on calcium - channel blockers: the COHORT study. Clin Cardiol 2003; 26 (Suppl. 2): II 17–20.Zanchetti A. Emerging data on calcium - channel blockers: the COHORT study. Clin Cardiol 2003; 26 (Suppl. 2): II 17–20.Toyo-Oka T, Nayler W.G. Third generation calcium entry blockers. Blood Pressure 1996; 5: 206–8.Toyo-Oka T, Nayler W.G. Third generation calcium entry blockers. Blood Pressure 1996; 5: 206–8.Acanfora D, Trojano L, Gheorghiade M et al. A randomized, double - blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther 2002; 9 (5): 444–53.Acanfora D, Trojano L, Gheorghiade M et al. A randomized, double - blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther 2002; 9 (5): 444–53.Barbagallo M, Sangiorgi G.B. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.Barbagallo M, Sangiorgi G.B. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.Borghi С, Prandin M.G, Dormi A et al. The use of lercanidipine can improve the individual tolerability in dihydropyridine calcium blockers in hypertensive patients. J Hypertenmsion 2000; 18 (Suppl. 2): S155–S156.Borghi С, Prandin M.G, Dormi A et al. The use of lercanidipine can improve the individual tolerability in dihydropyridine calcium blockers in hypertensive patients. J Hypertenmsion 2000; 18 (Suppl. 2): S155–S156.Fogari R, Mugellini A, Zoppi A et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596–9.Fogari R, Mugellini A, Zoppi A et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596–9.Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison and in combination with atenolol in patients with mild to moderate hypertension in double - blind controlled study. J Cardiovascul Pharmacol 1997; 29 (Suppl. 2): S26–S30.Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison and in combination with atenolol in patients with mild to moderate hypertension in double - blind controlled study. J Cardiovascul Pharmacol 1997; 29 (Suppl. 2): S26–S30.Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovascul Pharmacol 1997; 29 (Suppl. 2): S50–S53.Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovascul Pharmacol 1997; 29 (Suppl. 2): S50–S53.Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in comparison and in combination with atenolol in patients with mild to moderate essential hypertension: a comparative study with slow - release nifedipine. J Cardiovascul Pharmacol 1997; 29 (Suppl. 2): S31–S35.Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in comparison and in combination with atenolol in patients with mild to moderate essential hypertension: a comparative study with slow - release nifedipine. J Cardiovascul Pharmacol 1997; 29 (Suppl. 2): S31–S35.Romito R, Pansini M, Perticone F et al. Comparative effect of lercanidipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: The Lercanidipine in Adults (LEAD) Study. J Clin Hyprtens 2003; 5 (4): 249–53.Romito R, Pansini M, Perticone F et al. Comparative effect of lercanidipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: The Lercanidipine in Adults (LEAD) Study. J Clin Hyprtens 2003; 5 (4): 249–53.

The authors declare that there are no conflicts of interest present.